Drug Makers In India

Generic drugmakers to slash price plans as Novo cuts Wegovy rates

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

CDSCO tells drugmakers to meet global norms by Jan after cough syrup deaths

The government had directed drugmakers in late 2023 to upgrade plants to World Health Organization-recommended norms

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Centre refuses deadline extension for pharma firms after Coldrif deaths

The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities

Balaji Amines accused of making pharma-grade chemical without licence

Balaji said it had tested its PG using US and Indian pharma standards at the behest of its non-pharma clients, and this was the reason why those standards were mentioned in its PG labels

One shot every six months: India could change HIV prevention forever

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of generic production

Indian drugmakers gear up for ₹600-800 cr insulin pen market post-Novo exit

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore market opportunity from FY26 onwards

India's bulk drug makers start preparing for Ozempic patent expiry

From local giants Dr Reddy's Laboratories Ltd. to suppliers like Macleods Pharmaceuticals Ltd., Indian firms are preparing to make bulk drugs

India launches formal rules to fix, streamline drug and device clearances

India has issued first official guidelines for expert panels to bring consistency, speed, and transparency to drug and device approvals amid a broader regulatory overhaul

Cipla to enter weight management segment in India: MD & Global CEO Vohra

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche indications...obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug ...

Aurobindo Pharma recalls over 4,600 bottles of painkiller in US market

The drug, Acetaminophen Tablets (325 mg), is being recalled due to manufacturing deviations from Current Good Manufacturing Practices, following complaints of brown tablet discolouration

Drugmakers may lose product licence if govt labs flag quality failures

The Health Ministry is working with states to allow immediate suspension of licences for drugs declared substandard by labs, following a key recommendation from Drugs Technical Advisory Board

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India

The 1.75 mg and 2.4 mg doses will be priced at ₹24,280, and 2.4 mg will be priced at ₹26,050 for a month

Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20

Serum Institute signs MoU with DNDi to develop dengue treatment candidate

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, Brazil and other endemic countries

Hypertension, anti allergy meds among 196 drugs flagged by CDSCO as NSQ

Monthly CDSCO alert identifies 196 batches of drugs as not of standard quality and flags one Deca-Durabolin injection as spurious and under investigation

Schedule M rollout may face delay as MSMEs seek more time for upgrade

Small drugmakers seek a three-month extension to submit GMP compliance plans under revised Schedule M, raising concerns about delays in national rollout

Dr Reddy's Laboratories, Sanofi Healthcare partner for respiratory drug

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country

CDSCO flags spurious batch of Telma, 131 other drugs fail quality tests

One of the popular hypertension medication brands Telma 40 samples were found to be spurious in raids across locations

Biocon subsidiary secures permission to launch eye medicine Yesafili in US

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says